bluebird bio, Inc. (BLUE)
NASDAQ: BLUE · Real-Time Price · USD
4.970
0.00 (0.00%)
At close: May 16, 2025, 4:00 PM
4.970
0.00 (0.00%)
After-hours: May 16, 2025, 4:01 PM EDT
bluebird bio Revenue
In the year 2024, bluebird bio had annual revenue of $83.81M with 184.12% growth. bluebird bio had revenue of $38.52M in the quarter ending December 31, 2024, with 391.72% growth.
Revenue (ttm)
$83.81M
Revenue Growth
+184.12%
P/S Ratio
0.46
Revenue / Employee
$419,137
Employees
248
Market Cap
48.66M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
BLUE News
- 2 days ago - Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital - Reuters
- 2 days ago - Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement - Business Wire
- 7 days ago - Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital - Business Wire
- 11 days ago - Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio - Business Wire
- 4 weeks ago - bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement - Business Wire
- 6 weeks ago - Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps - Benzinga
- 6 weeks ago - Bluebird bio receives non-binding bid for up to $110.5 million - Reuters
- 6 weeks ago - Bluebird Bio Reviewing Buyout Offer From Ayrmid for Up to $110.5 Million -- Update - Market Watch